TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06518239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peep Belt
Description: Belt will be placed on the nipple line of the patient prior to the surgery start in the operating room. Data will be collected prior to the initial incision after the patient has been intubated, and then at the end of surgery before the patient has been extubated.
Study: NCT05165667

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation team
Description: The meeting comprised physiotherapist, occupational therapist, rehabilitation nurse, speech and language therapists, social worker, nutritionist, psychologists under the team leader guidance by physiatrist. Respondents of both groups will be assessed to see the effects of treatment at 6 th weeks, 12 th weeks and 24 th weeks. Outcomes will be measured by FIM (Functional independence Measure) scores.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation team
Description: The meeting comprised physiotherapist, occupational therapist, rehabilitation nurse, speech and language therapists, social worker, nutritionist, psychologists under the team leader guidance by physiatrist. Respondents of both groups will be assessed to see the effects of treatment at 6 th weeks, 12 th weeks and 24 th weeks. Outcomes will be measured by FIM (Functional independence Measure) scores.
Study: NCT05814666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danvatirsen
Description: Danvatirsen is a STAT3 targeting drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2
Study: NCT05325801

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMCA and GPRC5D dual target CAR-T cells(OriC321)
Description: Patients will receive lymphodepleting chemotherapy followed by a single infusion of OriC321
Study: NCT05306405

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Tablet
Description: Misoprostol alone will be repeated every 4 h in both groups for a maximum of 5 doses, reaching Bishop score \>8, rupture of membranes or occurrence of labor pain.~Cervical evaluation will be done using Bishop's score. A score \< 5 will be taken as unfavorable Cervix will be termed as ripped when Bishop's score equal 8 or more.~The endpoint of the study will be initiation of active phase of 1st stage of labor which commence from 6cm to full cervical dilatation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Tablet
Description: Misoprostol alone will be repeated every 4 h in both groups for a maximum of 5 doses, reaching Bishop score \>8, rupture of membranes or occurrence of labor pain.~Cervical evaluation will be done using Bishop's score. A score \< 5 will be taken as unfavorable Cervix will be termed as ripped when Bishop's score equal 8 or more.~The endpoint of the study will be initiation of active phase of 1st stage of labor which commence from 6cm to full cervical dilatation
Study: NCT06366711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pregnabit Pro device and PregnaOne platform
Description: Remote CTG device for pregnancy care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pregnabit Pro device and PregnaOne platform
Description: Remote CTG device for pregnancy care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulsenmore device
Description: Remote ultrasound device for pregnancy care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulsenmore device
Description: Remote ultrasound device for pregnancy care
Study: NCT06253351

Intervention type: DEVICE
Intervention: Hybrid closed loop (HCL)
Description: * Control IQ : T-Slim pump with Dexcom G6~* Smartguard : Medtronic 780G pump with Guardian G4S~* Diabeloop : Kaliedo pump with Dexcom G6
Study: NCT06442475

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood, oral, and/or rectal sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT or CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06548230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadunolimab
Description: Give by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadunolimab
Description: Give by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadunolimab
Description: Give by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadunolimab
Description: Give by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by mouth (PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by mouth (PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by mouth (PO
Study: NCT06388226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leg heat therapy
Description: A sous vide heating immersion circulator heats up the water inside the water tank to 42ºC. A water pump circulates temperature-regulated water through the trousers.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Leg sham therapy
Description: A sous vide heating immersion circulator heats up the water inside the water tank to 33ºC. A water pump circulates temperature-regulated water through the trousers.
Study: NCT05388110

Intervention type: BEHAVIORAL
Intervention: SKY Breath Intervention
Description: Sudarshan Kriya Yoga (SKY) is a breath-based meditative practice that entails a sequence of specific breathing techniques to help practitioners achieve a state of calm alertness. It has offered benefits as a therapeutic option for mild-to-moderate depression and anxiety disorders and as an adjunctive treatment in patients with major depressive disorder, but the neurological mechanism of SKY breath intervention is still not fully understood.

Intervention type: BEHAVIORAL
Intervention: SKY Breath Intervention
Description: Sudarshan Kriya Yoga (SKY) is a breath-based meditative practice that entails a sequence of specific breathing techniques to help practitioners achieve a state of calm alertness. It has offered benefits as a therapeutic option for mild-to-moderate depression and anxiety disorders and as an adjunctive treatment in patients with major depressive disorder, but the neurological mechanism of SKY breath intervention is still not fully understood.
Study: NCT04945733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered intravenously.
Study: NCT05531656

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT1812
Description: Study Drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT1812
Description: Study Drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active study drug
Study: NCT05446129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezabenlimab
Description: Ezabenlimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765063
Description: BI 765063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765063
Description: BI 765063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab
Study: NCT06556121

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saddle block
Description: The injected solution will be comprised of 5mg of heavy Bupivacaine 0.75% plus 100mcg of Morphine will be injected into the intrathecal space.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: pudendal nerve block
Description: As part of the analgesic plan, all patients will receive a multimodal analgesic regimen with acetaminophen, NSAIDs and opioids plus a surgeon-administered pudendal nerve block by anatomical landmarks with a mixture of Local Anesthetic as follows: 50mL of Normal Saline, 30mL of 0.25% Bupivacaine with epinephrine 1:200.000 and 20mL Lidocaine 1%. A volume of 20 mL of this mixture is used for the pudendal nerve block, and infiltration of the surgical incision and bilateral spermatic cord block is performed with an additional 20 mL of the same mixture of local anesthetic. 30ml of the solution is used to soak the vaginal plug made of gauze that is put inside the vaginal canal by the end of the procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pudendal nerve block
Description: As part of the analgesic plan, all patients will receive a multimodal analgesic regimen with acetaminophen, NSAIDs and opioids plus a surgeon-administered pudendal nerve block by anatomical landmarks with a mixture of Local Anesthetic as follows: 50mL of Normal Saline, 30mL of 0.25% Bupivacaine with epinephrine 1:200.000 and 20mL Lidocaine 1%. A volume of 20 mL of this mixture is used for the pudendal nerve block, and infiltration of the surgical incision and bilateral spermatic cord block is performed with an additional 20 mL of the same mixture of local anesthetic. 30ml of the solution is used to soak the vaginal plug made of gauze that is put inside the vaginal canal by the end of the procedure.
Study: NCT05820581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentalisation
Description: Hypomentalisation, hypermentalisation, correct mentalisation, lack of mentalisation
Study: NCT06116045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BZ371A 7.5 mg (1.5 ml)
Description: 7.5 mg gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BZ371A 7.5 mg (1.5 ml)
Description: 7.5 mg gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BZ371A 5.0 mg (1.0 ml)
Description: 5.0 mg gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BZ371A 5.0 mg (1.0 ml)
Description: 5.0 mg gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BZ371A 2.5 mg (0.5 ml)
Description: 2.5 mg gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BZ371A 2.5 mg (0.5 ml)
Description: 2.5 mg gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (1.5 ml)
Description: BZ371A-matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (1.5 ml)
Description: BZ371A-matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (1.0 ml)
Description: BZ371A-matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (1.0 ml)
Description: BZ371A-matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (0.5 ml)
Description: BZ371A-matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (0.5 ml)
Description: BZ371A-matched placebo
Study: NCT06562790

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gamma PN3
Description: 500, 1000 or 1500 µg by IM injection on Days 1 and 29

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar
Description: 1 dose on Day 1 and saline placebo on Day 29
Study: NCT06363461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDM-180935 topical ointment 1.0%
Description: Eligible patients in the randomized portion of the study will be randomized (2:2:1:1) to 1 of the 4 groups. The assigned drug will be applied once daily for 8 weeks, with application to the active lesions excluding head/neck, hands/feet, genitalia, and intertriginous areas.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDM-180935 topical ointment 2.0%
Description: Eligible patients in the randomized portion of the study will be randomized (2:2:1:1) to 1 of the 4 groups. The assigned drug will be applied once daily for 8 weeks, with application to the active lesions excluding head/neck, hands/feet, genitalia, and intertriginous areas.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TDM-180935 topical vehicle ointment 1
Description: Eligible patients in the randomized portion of the study will be randomized (2:2:1:1) to 1 of the 4 groups. The assigned placebo will be applied once daily for 8 weeks, with application to the active lesions excluding head/neck, hands/feet, genitalia, and intertriginous areas.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TDM-180935 topical vehicle ointment 2
Description: Eligible patients in the randomized portion of the study will be randomized (2:2:1:1) to 1 of the 4 groups. The assigned placebo will be applied once daily for 8 weeks, with application to the active lesions excluding head/neck, hands/feet, genitalia, and intertriginous areas.
Study: NCT04873037

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BTL Emsella Chair
Description: The Emsella Chair is a novel high-intensity focused electromagnetic (HIFEM) technology for the treatment of pelvic floor related disorders. HIFEM technology induces deep pelvic floor muscle contractions designed to deliver the equivalent of 11,200 Kegel exercises over 28 minutes. The treatment paradigm consists of 3 different phases. The phases consist of an intense stimulation of the pelvic floor muscles (PFM), which consists of stimulation and relaxation. The repetition of the phases and focused electromagnetic energy delivery leads to pelvic floor stimulation, adaptation, and remodelation.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham BTL Emsella Chair
Description: The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below therapeutic level (less than 10%) power.
Study: NCT04665999

Intervention type: DEVICE
Intervention: Continuous Glucose Monitor
Description: Data collection only
Study: NCT04649229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Placebo or aprepitant 120 mg will be given orally on study days 1 and 2 and again on study days 3 and 4
Study: NCT05217498

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Istradefylline
Description: Consume 20mg tablet of istradefylline for 28 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istradefylline
Description: Consume 20mg tablet of istradefylline for 28 consecutive days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low oxygen therapy
Description: Breath intermittent low oxygen 4 days/week over 2 consecutive weeks. Intermittent low oxygen consists of 15, 90-second episodes of breathing low oxygen at 10% oxygen with 60-second intervals at 21% oxygen.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low oxygen therapy
Description: Breath intermittent low oxygen 4 days/week over 2 consecutive weeks. Intermittent low oxygen consists of 15, 90-second episodes of breathing low oxygen at 10% oxygen with 60-second intervals at 21% oxygen.
Study: NCT06359834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: Patients in this group receives 0.1mg/kg of remimazolam to induce sedation prior to endoscope insertion. Remimazolam 2mg is added in case of inadequate sedation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Patients in this group receives 1mg/kg of propofol to induce sedation prior to endoscope insertion. Propofol 20mg is added in case of inadequate sedation.
Study: NCT05237960

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Release Metformin Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study: NCT06487988

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: direct conventional laryngoscopy
Description: direct conventional laryngoscopy will be performed with N3 (for females) or N4 (for males) Macintosh laryngoscope blade.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fiberoptic guided intubation
Description: fiberoptic guided intubation will be performed.
Study: NCT05983965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Treatment: On day 1 and day 15 of the first cycle, and day 1 of all following cycles, the subject will have office visit with physical exam, vital signs, and lab tests. The subject will take tazemetostat twice a day by mouth continuously as an outpatient. If continuing on the treatment for more than 6 cycles, visits change to every 3 months.
Study: NCT06504628

Intervention type: DIAGNOSTIC_TEST
Intervention: screening risk for falling and identifiy the risk level low-intermediate-high
Description: 3 key questions: Any posiitve answer to a) Has fallen in the past year? b) Feels unsteady when standing or walking? or c) Worries about falling? prompts to fall severity step.~if no at the three questions= low level of fall-risk Fall severity: fall with injuires, laying on the ground with no capacity to get up, or a visit to emergency room, or loss of conscienciousness/suspected syncope. or Frailty (Clinical Frailty Scale)= if positive, high risk otherwise, 4 meter-walk test: if =\<0.8m/sec= intermediate risk if \>0.8m/sec=intermediate risk

Intervention type: DIAGNOSTIC_TEST
Intervention: screening risk for falling and identifiy the risk level low-intermediate-high
Description: 3 key questions: Any posiitve answer to a) Has fallen in the past year? b) Feels unsteady when standing or walking? or c) Worries about falling? prompts to fall severity step.~if no at the three questions= low level of fall-risk Fall severity: fall with injuires, laying on the ground with no capacity to get up, or a visit to emergency room, or loss of conscienciousness/suspected syncope. or Frailty (Clinical Frailty Scale)= if positive, high risk otherwise, 4 meter-walk test: if =\<0.8m/sec= intermediate risk if \>0.8m/sec=intermediate risk

Intervention type: DIAGNOSTIC_TEST
Intervention: screening risk for falling and identifiy the risk level low-intermediate-high
Description: 3 key questions: Any posiitve answer to a) Has fallen in the past year? b) Feels unsteady when standing or walking? or c) Worries about falling? prompts to fall severity step.~if no at the three questions= low level of fall-risk Fall severity: fall with injuires, laying on the ground with no capacity to get up, or a visit to emergency room, or loss of conscienciousness/suspected syncope. or Frailty (Clinical Frailty Scale)= if positive, high risk otherwise, 4 meter-walk test: if =\<0.8m/sec= intermediate risk if \>0.8m/sec=intermediate risk

Intervention type: DIAGNOSTIC_TEST
Intervention: 3 mnth-follow-up
Description: patient's phone call, and data collected from electronic medical record
Study: NCT06540742

Intervention type: DIAGNOSTIC_TEST
Intervention: Artificial intelligence identifies liver hydatids
Description: Artificial neural network was constructed to automatically identify liver hydatid by using deep learning technology

Intervention type: DIAGNOSTIC_TEST
Intervention: Artificial intelligence identifies liver hydatids
Description: Artificial neural network was constructed to automatically identify liver hydatid by using deep learning technology
Study: NCT06543745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-Resistance Training
Description: The following 6 exercises will be performed in 3 sets of 15-15-15 repetitions, 3 times per week for 12 weeks:~Elbow Flexion, Elbow Extension, Lateral Hip Extensions, Hip Extensions, Knee Extensions, Wall push-ups
Study: NCT06545188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mortality Attitudes Personality Survey
Description: Two open questions about death and mortality will bei administered to trigger mortality salience

Intervention type: OTHER
Group type: OTHER
Intervention: Dental treatment questions (control condition)
Description: Two open questions about a dental treatment (control condition)
Study: NCT05367778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10370
Description: HS-10370 will be administered orally once daily in a continuous regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10370
Description: HS-10370 will be administered orally once daily in a continuous regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10370
Description: HS-10370 will be administered orally once daily in a continuous regimen
Study: NCT05083741

Intervention type: DEVICE
Intervention: Chitogel
Description: post-operative dressing within standard of care

Intervention type: DEVICE
Intervention: Nexfoam
Description: post-operative dressing within standard of care
Study: NCT06584968

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training with visual feedback
Description: Training with visual feedback by comparing the value of the monofilament with the pressure value of the monofilament applied on the precision scale in grams.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: classical learning
Description: Study of the test with practical applications on the researcher who plays the role of the patient
Study: NCT06584552

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus Paracasei LPB27
Description: Probiotic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Placebo
Study: NCT05494788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CardiolRx
Description: Pharmaceutically produced Cannabidiol
Study: NCT06396884

Intervention type: DEVICE
Intervention: Oscillometric intermittent non-invasive blood pressure
Description: The hemodynamic management followed liberal fluid therapy, as determined by the attending anesthetist's discretion

Intervention type: DEVICE
Intervention: ClearSight
Description: The hemodynamic management will be conducted in accordance to a goal-directed fluid therapy (GDFT) utilizing the Clearsight system monitoring.